New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Pfizer Inc.

PFE

Healthcare Drug Manufacturers General

Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024.

Revenue
−0.43%
EPS
−9.68%
Free cash flow
+20.0%
Total debt
+1.55%

Quarter to September 2026, against a year earlier

27.71 0.14 +0.51%
Market cap
$158.2B
P/E
38.8×
Fwd P/E FY26e
18.7×
Dividend yield
6.24%
F-score
6/9
ROIC
6.19%
Net debt / EBITDA
2.5×
Payout ratio
2.5×

Revenue to profit Q3 FY2026, quarter to Sep 30, 2026

Of every $100 of revenue, $19.61 was left as profit. What is an income statement?

Revenue to profit, in billions of dollars and as a share of revenue
Revenue16.6100.0%
Cost of revenue−4.0−24.3%
Gross profit12.675.7%
Research & development−3.0−18.2%
Selling, general & admin−3.3−19.8%
Other operating costs−2.6−15.6%
Operating income3.722.1%
Other income, net−0.3−1.7%
Income tax−0.1−0.8%
Net income3.319.6%
RevenueOperating incomeNet incomeNet margin (right axis)
Revenue, operating income and net income, four quarters
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Revenue$17.6B$14.5B$15.0B$16.6B
Operating income$2.9B$4.0B$3.1B$3.7B
Net income−$1.6B$2.7B−$238M$3.3B
Net margin (right axis)−9.3%18.7%−1.6%19.6%
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
Revenue
16,583.00 15,034.00 14,451.00 17,557.00

+8 more quarters

Revenue Growth
(0.43%) 2.60% 5.37% (1.16%)
Cost of Revenue
4,028.00 4,092.00 3,548.00 5,272.00
Gross Profit
12,555.00 10,942.00 10,903.00 12,285.00
R&D Expenses
3,016.00 2,809.00 2,490.00 3,206.00
SG&A Expenses
3,279.00 3,411.00 2,961.00 4,162.00
Operating Income
3,672.00 3,064.00 4,032.00 2,872.00
Non-operating Income/Expense
(288.00) (3,716.00) (861.00) (4,515.00)
EBT
3,385.00 (653.00) 3,170.00 (1,643.00)
Income Tax Provision
134.00 (407.00) 461.00 (2.00)
Income after Tax
3,251.00 (246.00) 2,709.00 (1,641.00)
Dividends (Preferred)
— 1.00 1.00 —
Non-Controlling Interest
10.00 10.00 8.00 8.00
Net Income Common
3,242.00 (248.00) 2,687.00 (1,647.00)
EPS (Basic)
0.57 (0.04) 0.47 (0.29)
EPS (Diluted)
0.56 (0.04) 0.47 (0.29)
Shares (Basic, Weighted)
5,700.00 5,699.00 5,691.00 5,683.00
Shares (Diluted, Weighted)
5,751.00 5,699.00 5,731.00 5,713.00
Gross Margin
75.71% 72.78% 75.45% 69.97%
EBIT Margin
22.14% 20.38% 27.90% 16.36%
EBT margin
20.41% (4.34%) 21.94% (9.36%)
Net Profit Margin
19.55% (1.65%) 18.59% (9.38%)
EBITDA
5,249.00 4,686.00 5,645.00 4,559.00
EBIT
3,672.00 3,064.00 4,032.00 2,872.00
Income from Continuous Operations
3,251.00 (246.00) 2,709.00 (1,639.00)
Income from Discontinued Operations
0.00 8.00 (13.00) —
Consolidated Net Income/Loss
3,252.00 (237.00) 2,696.00 (1,639.00)
EPS (Basic, from Continuous Ops)
0.57 (0.04) 0.48 (0.28)
EPS (Diluted, from Cont. Ops)
0.56 (0.04) 0.47 (0.29)
EPS (Diluted, from Disc. Ops)
0.00 0.00 0.00 —
EPS (Basic, from Discontinued Ops)
0.00 0.00 0.00 —
EPS (Basic, Consolidated)
0.57 (0.04) 0.47 (0.29)
EPS (Diluted, Consolidated)
0.57 (0.04) 0.47 (0.29)
Shares (Diluted, Average)
5,751.00 5,699.00 5,731.00 5,686.00
EBITDA Margin
31.65% 31.17% 39.06% 25.97%
Operating Cash Flow Margin
32.41% 5.55% 18.10% 30.46%

Fold the line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026